Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note released on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Several other research analysts also recently commented on the company. Brookline Capital Management downgraded Cyclacel Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, December 19th. Roth Mkm raised their price objective on Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a buy rating in a report on Tuesday, December 19th.

Cyclacel Pharmaceuticals Stock Performance

Shares of CYCC stock opened at $1.67 on Tuesday. Cyclacel Pharmaceuticals has a 52-week low of $1.52 and a 52-week high of $13.20. The firm has a market capitalization of $2.20 million, a P/E ratio of -0.06 and a beta of 0.54. The stock has a 50 day moving average price of $2.37 and a 200 day moving average price of $3.99.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The business had revenue of $0.03 million for the quarter. As a group, sell-side analysts forecast that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of Cyclacel Pharmaceuticals in the 2nd quarter valued at $33,000. HRT Financial LP purchased a new position in shares of Cyclacel Pharmaceuticals in the 4th quarter valued at $27,000. Renaissance Technologies LLC acquired a new stake in shares of Cyclacel Pharmaceuticals in the 2nd quarter worth $68,000. Two Sigma Investments LP acquired a new stake in shares of Cyclacel Pharmaceuticals in the 3rd quarter worth $98,000. Finally, Millennium Management LLC acquired a new stake in shares of Cyclacel Pharmaceuticals in the 2nd quarter worth $113,000. 23.58% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.